HOME >> MEDICINE >> NEWS
Study shows possible link between Parkinson's medication and cardiac valve disease

SAN FRANCISCO A recent study of Parkinson's disease patients who use the medication pergolide shows a possible link between pergolide and injured cardiac valves. Study details and conclusions will be presented at the American Academy of Neurology 56th Annual Meeting in San Francisco, Calif., April 24 May 1, 2004.

Valvular heart disease has been reported by various groups, totaling about 25 patients with Parkinson's disease who take pergolide. "These reports are anecdotal, from uncontrolled case studies," notes study author Richard B. Dewey, Jr., MD, associate professor of neurology, University of Texas Southwestern Medical Center in Dallas. "We were interested to know if this is a rare, idiosyncratic event or a common problem which has until now escaped notice."

Dewey and fellow researchers sent letters to more than 200 patients known to be taking pergolide for Parkinson's disease, and the responders who wished to continue pergolide were urged to undergo echocardiography. Echocardiograms were performed on 46 patients, and scores for valvular regurgitation (leakage) were compared to an age-matched control group from the Framingham Study (a well-documented heart disease study).

Two outcomes were compared: the presence of abnormal valvular leakage; and the presence of clinically significant leakage using criteria similar to that employed by the FDA in the fenfluramine/ phentermine ("Fen-Phen" diet aid) studies.

Eighty-nine percent (41) of pergolide-treated patients had some degree of valvular insufficiency. In two of three valves for which there is control data (the mitral and aortic), the study showed an approximately two- to three-fold increased risk (odds ratio 3) of regurgitation in the pergolide patients. In the tricuspid valve there was an estimated 14-fold increased risk of significant leakage (odds ratio 18).

"Our study demonstrates that pergolide may injure cardiac valves and, since they are available, consideration sh
'"/>

Contact: Kathy Stone
kstone@aan.com
651-695-2763
American Academy of Neurology
28-Apr-2004


Page: 1 2

Related medicine news :

1. Study of energy and health in Africa focuses spotlight on charcoal and forest management
2. Study shows promise in identifying kidney failure
3. Study shows patch therapy may be as effective as oral medications
4. Study shows soy is well accepted in school lunches
5. Study finds that coordinating care of chronically ill patients does not increase liability
6. Study provides new estimates of the causes of child mortality worldwide
7. Study finds factors linked to substance use disorder relapse among health care professionals
8. Study finds majority of women willing to accept cervical cancer vaccine for self and children
9. Study shows use of budesonide reduced the risk of asthma related events by 40% in children
10. Study shows risk of cardiac death after radiation for breast cancer has dramatically decreased
11. Study shows acrylamide in baked and fried food does not increase risk of breast cancer in women

Post Your Comments:
(Date:4/23/2014)... "simple and accessible detection methods that can rapidly ... of a single cell inside that population has ... Chang Lu. , In the Royal Society of ... announced that he and his coworkers have developed ... of a protein ( Chem. Sci. , 2014, ...
(Date:4/23/2014)... are often displayed in the popular Swedish children,s ... of high-sugar foods. A new study from the ... in children,s TV programmes as well as the ... and weight status. , Steingerdur Olafsdottir,s doctoral thesis ... popular Swedish children,s TV show Bolibompa. Healthy foods ...
(Date:4/23/2014)... led by a researcher from the Cancer Science Institute ... Singapore has identified the cancer specific stem cell which ... of developing new drugs for the treatment of this ... group, led by Dr Chan Shing Leng, Research Assistant ... that a cancer-specific variant of a cell surface protein, ...
(Date:4/23/2014)... in the journal Oncotarget , explored tumour ... or their own DNA signatures within the same ... design effective, targeted treatment strategies. , Firstly they ... and either the KRAS or BRAF mutation. Secondly, ... EGFR gene mutation have that specific mutation present ...
(Date:4/23/2014)... Alzheimer,s disease has been a rapidly evolving pursuit ... latest crook in the research road, scientists have ... proteins associated with the disease. The report, which ... , could have important implications for developing novel ... colleagues explain that for years, research has suggested ...
Breaking Medicine News(10 mins):Health News:Following a protein's travel inside cells is key to improving patient monitoring, drug development 2Health News:High-calorie and low-nutrient foods in kids' TV 2Health News:Scientists identify cancer specific cell for potential treatment of gastric cancer 2Health News:Scientists identify cancer specific cell for potential treatment of gastric cancer 3Health News:Non-uniform genetic mutations identified in lung cancers could lead to targeted treatment 2
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Forecast and Market Analysis to 2022 ... Atopic Dermatitis - India Drug Forecast and ...
(Date:1/15/2014)... , Jan. 15, 2014  Zafgen, Inc., a ... needs of severely obese patients, today announced initial ... a selective inhibitor of methionine aminopeptidase 2 (MetAP2), ... form of genetic obesity.  These results showed improvements ...
(Date:1/14/2014)... InformEx, North America,s leading business partnering ... the 30 th edition of its annual conference at ... January 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ) ... and specialty chemical companies will take part in the conference, ...
Breaking Medicine Technology:PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
Cached News: